NICE recommends rivaroxaban for stroke prevention in AF

Rivaroxaban (Xarelto) has been approved by NICE for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF).

Xarelto (rivaroxaban) is taken orally once daily with food and does not require regular anticoagulation monitoring
Xarelto (rivaroxaban) is taken orally once daily with food and does not require regular anticoagulation monitoring
The anticoagulant can be used in patients with non-valvular AF with one or more of the following risk factors:
•    Previous stroke or transient ischaemic attack
•    Congestive heart failure
•    Age 75 years or older
•    Diabetes
•    Hypertension.

Rivaroxaban is also recommended by NICE at a lower dose for the prevention of venous thromboembolism following elective total hip or knee replacement surgery.            

Further details
NICE guidance on rivaroxaban in atrial fibrillation

Further information:
View Xarelto drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Xarelto: first novel anticoagulant licensed for ACS

Xarelto: first novel anticoagulant licensed for ACS

Bayer has launched a new 2.5mg strength of Xarelto...

Xarelto licensed to treat pulmonary embolism

Xarelto licensed to treat pulmonary embolism

Xarelto (rivaroxaban) can now be prescribed for the...

NICE approves rivaroxaban for DVT and recurrent VTE

NICE approves rivaroxaban for DVT and recurrent VTE

The direct factor Xa inhibitor rivaroxaban has been...

Latest SMC recommendations released

Latest SMC recommendations released

The SMC has accepted products licensed for type II...

Xarelto: two new indications for oral anticoagulant

Xarelto: two new indications for oral anticoagulant

The direct oral factor Xa inhibitor, rivaroxaban (Xarelto),...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases